No description available.

The role of cyclic guanosine monophosphate (cGMP) dependent protein kinase (PKG) in necrotic and apoptotic pathways of many cell types is well established; however its role in the ischemic preconditioning (IPC) of cardiomyocytes is not clearly defined. In the current study, we assessed the hypothesis that PKG protects against cell death following ischemidreperfusion injury in myocytes subjected to IPC. Freshly isolated adult rat ventricular myocytes were subjected to IPC by incubating in ischemic buffer for 30 minutes (min) followed by incubation in normal medium for 30 min. Prolonged simulated ischemia (SI) was created by incubating myocytes in the ischemic buffer for 90 min and reoxygenation (RO) for 120 min in the normal medium. Necrosis was determined by trypan blue exclusion and apoptosis was assessed by TUNEL assay. IPC reduced necrosis as shown by significant decrease in trypan blue positive cells as compared to virgin non-preconditioned myocytes subjected to SI and RO alone (p<.01). Similarly, the number of TUNEL positive myocytes following SI and 18 hrs of RO were significantly reduced in the IPC group. Treatment with PKG inhibitor, KT5832 (2pM) completely abolished the protection against necrosis by IPC. However, KT5832 failed to abolish the protective affect of IPC against apoptosis. Furthermore, myocytes infected with an adenoviral construct of PKG-la (1 x 1 o4 particles/cell) significantly reduced the number of trypan blue and TUNEL positive cells. These results suggest that the PKG signaling pathway plays an essential role in the preconditioning of myocytes against necrosis following SI / RO injury. Furthermore, while the overexpression of PKG protects myocytes against necrosis, as well as apoptosis, IPC may not induce a sufficient level of PKG during 18 hours of RO to induce protection against apoptosis.

EN The growing emergence of bacteria resistant to conventional antibiotics is very alarming. This has prompted an intensive search for alternative antimicrobial agents which kill bacteria with different modes of action than do traditional antibiotics and do not develop drug resistance. Among these, antimicrobial peptides (AMPs) are considered as promising compounds against resistant pathogens. These positively charged peptides permeabilize or disrupt bacterial cell envelope which leads to leakage of cytoplasmic components and cell death. The aim of my dissertation thesis was the study of the action mechanism of novel antimicrobial peptides which I have isolated from the venom of different wild bees. I identified six novel AMPs which were named panurgines (PNG), codesane (COD) and antapines (ANTPs). These peptides were isolated from the venom of three different bee species (Panurgus calcaratus, Collete daviesanus and Anthophora plumipes). I was also involved in the structural studies of lasiocepsin (Las), the antimicrobial peptide identified in the venom earlier in our laboratory. All studied peptides possess activity against various strains of bacteria and low or moderate hemolytic activity. We prepared series of PNG, COD and ANTP analogs in order to study the effect of physicochemical properties...

This thesis reports on the combined effects of toxicants and physicochemical factors on micro-organisms. The main objective of the project was to use multi-sensing systems such as mediated and non-mediated sensor systems, growth tests and physicochemical sensors to investigate novel stressor-toxicant-assay combinations. Screen-printed, disposable, developmental-phase, physicochemical sensor constructs (conductivity and dissolved oxygen) were validated under conditions compatible with microbial bioassays, to ascertain their potential role in toxicity testing. The conductivity sensor construct could be used to indirectly inform on the osmolality of the test samples, but the dissolved oxygen sensor construct was not found to give reproducible results. The results were thought to be compromised by in-house screen-printing using a complex carbon ink formulation for the working electrode. Escherichia coli and a consortium with ammonia oxidation capacity (CAOC) were used as the test species for the bioassays. The combined effects of four inorganic salts (NaCl, NaN03, KCl and KN03) and two toxicants (3,5-DCP and HgCh) on E. coli were investigated using the CellSense™ biosensor system, Clark oxygen electrode and microtitre plate growth assays. A variety of trends were observed with each salt-toxicantbioassay combination, emphasising a need for better understanding of the assay media and factors such as bioavailability, to interpret the toxicity data. The results also suggested the importance of using multiple bioassays with varied end points, for toxicity testing. The CAOC, which was isolated from the activated sludge, was tested for physicochemical stressor and toxicant effects using the mediated biosensors. The results were very different from those obtained with E. coli, indicating that each species reacts to toxicants and changes in physicochemical factors differently. Although the full potential of disposable, physicochemical sensors, at the point of toxicity testing was not achieved, the study did investigate previously uncharacterised, combined effects of salts and toxicants on microbial cells. It highlighted the need for development of hybrid systems and also offered a route towards integration of physicochemical and biological sensing systems for simultaneous monitoring of both environmental and biological elements.

This dissertation discusses the development of inexpensive, easy-to-use, and field-deployable diagnostic techniques and devices for the early detection of various pathogens, commonly found in clinical samples and contaminated food and water. Infectious diseases account for about 90% of world health problems, killing approximately 14 million people annually, the majority of which reside in developing countries. In 2012, the World Health Organization (WHO) published data on the top 10 causes of death across the globe. Although communicable disease is a prevalent cause of fatality, both low-income and high-income countries, pathogen species and transmission are very different. Nearly 60% of deaths in developing countries are caused by food, water, air or blood-borne pathogens. The most prevalent illnesses are diarrheal disease, malaria, and HIV/AIDS. By contrast, the leading causes of death in developed countries (heart disease, cancer, and stroke) are not communicable and are often preventable. However, there is an increasing need for the development of rapid and accurate methods for pathogen identification in clinical samples, due to the growing prevalence of antibiotic-resistant strains. Incorrect, or unneeded antibiotic therapies result in the evolution of extremely aggressive nosocomial (hospital-acquired) infections, such as methicillin- (MRSA) and vancomycin-resistant Staphylococcus aureus (VRSA). The implementation of rapid, easy to use and cost-effective diagnostics will reduce the frequency of pathogen-related deaths in underdeveloped countries, and improve targeted antibiotic treatment in hospital settings, thus decreasing the potential development of more treatment-resistant "super bugs". This research includes novel techniques utilizing two major sensing modalities: serological (i.e. immunological), and nucleic acid amplification testing (NAATs). We first developed a highly sensitive (limit-of-detection = 100 CFU mL-1) particle immunoassay that takes advantage of elastic and inelastic light scatter phenomena, for optical detection of target antigens. This assay is performed upon a unique nanofibrous substrate that promotes multiplexing on a user-friendly platform. We then developed a novel technique, termed emulsion loop-mediated isothermal amplification (eLAMP), in which the target amplicon is detected in real-time, again utilizing light scattering detection and quantification. Both techniques require no sample pre-treatments, and can be combined with smartphone imaging for detection of targets in under 15 minutes. These methods have the potential to improve the speed and sensitivity of early pathogenic identification, thus leading to a reduction in preventative deaths and a decrease in global economic costs associated with infectious disease in clinical and other settings.

>Magister Scientiae - MSc / Tuberculosis (TB) is a global health problem and rated as the second leading cause of death after HIV/AIDS. Transmission of TB from one person to the next is very rapid in crowded communities. Therefore, it is crucial to identify people who are infected as quickly as possible not only to provide treatment but also to prevent the spread of the disease. Current TB diagnostic tests such as the culture and sputum smear tests are time-consuming, while rapid tests make use of antibodies that are costly and have low sensitivity and stability. Great improvement has been observed when aptamers are used in place of antibodies in rapid diagnostic tests such as lateral flow devices (LFDs). Therefore, the current study aims to synthesize and identify aptamers against serum biomarkers for development of rapid TB diagnostic tests such as a lateral flow assay. Several TB serum biomarkers have been identified and can be used for the diagnosis of TB. TB biomarkers expressed in serum samples were identified through in silico approach. The biomarkers were expressed in bacterial systems using recombinant DNA technology. The recombinant proteins were purified by affinity chromatography and further used as targets for the selection of aptamers using Systemic Evolution of Ligands by EXponential enrichment (SELEX). Aptamers for the selected biomarkers were synthesized based on magnetic-bead based SELEX and characterized by electrophoretic mobility shift assay (EMSA), Surface Plasmon resonance (SPR) and MicroScale Thermophoresis (MST). Six putative TB serum biomarker proteins were selected from literature, namely, Insulin-like Growth Factor Binding Protein 6 (IGFBP6), Interferon-stimulated Gene 15 (ISG15), Calcium Binding Protein (S100A9), Retinol Binding Protein 4 (RBP4), Granzyme A (GrA), and Transgelin-2 (TAGLN2). The biomarkers were recombinantly expressed and purified after which they were used as targets in SELEX for aptamers synthesis. Aptamers were analysed by in silico method and the ones with highly conserved motifs were selected. The selected aptamers were synthesized and later characterized. The aptamers that show high affinity and specificity for the biomarkers will be used for the fabrication of a rapid lateral flow device for TB screening. Such a test would allow for a short diagnostic turnaround time, and hence expedite treatment.

β-sitosterol/poly(ethylene glycol)-block-poly(lactic acid) (PLA-b-PEG) complexes were prepared by solution blending in purified water and ethanol. The mixture of water and ethanol is a suitable solvent system for the two components. The complex was studied by using Nuclear Magnetic Resonance (NMR) spectroscopy and Differential Scanning Calorimetry (DSC). β-sitosterol is a drug that may reduce the swelling of benign prostatic hyperplasia (BPH) and diminishing inflammation. However, it is hydrophobic and difficult to deliver in aqueous solution. Since PLA-b-PEG has amphiphilic properties, the complex described here may enhance delivery of this drug for treatment of BPH. Proton NMR (1HNMR) of the complexes shows that the methylene (CH2) protons of the PEG, the (-O-CH-) of PLA, and (CH3) of PLA are slightly shifted because of its non-covalent interaction with β-sitosterol. The complex formation was supported by 2-D NMR (NOESY) spectroscopy. NOESY spectra show cross peaks, indicating the interaction between the two components. DSC of the complexes shows thermal characteristics that are different from the individual components. In particular, the PEG in the complex shows a lower melting point and decreased crystallinity compared to the pure PEG. The melting point is lowered from 57°C to 55.3 °C for the PEG-b-PLA/β-sitosterol (5%) complex. Under the same condition, the melting point of PLA dropped from 170 °C to 130 °C. Atomic force microscopy shows changes in the surface morphology of the copolymer from crystalline to amorphous when incorporated with the drug. NMR, DSC, AFM, and MTT assay studies suggest the formation of a relatively stable β-sitosterol/poly(lactic acid)-block-poly(ethylene glycol) complex. The cell proliferation assay (MTT assay) suggests significant inhibition of the stimulation of growth of prostate cancer cells upon addition the complex.

Nos últimos anos têm crescido cada vez mais o número de pesquisas envolvendo nanotecnologia para obtenção de medicamentos com liberação controlada, pois esses sistemas podem: proteger o fármaco de incompatibilidades tanto biológicas quanto físico-químicas assim como controlar a biodisponibilidade do fármaco. Embora com todas essas vantagens não existem métodos in vitro realmente capazes de prever com precisão a liberação dos fármacos por esses sistemas, por esse motivo, é muito importante o desenvolvimento de métodos de liberação in vitro para determinar a cinética de liberação desses sistemas.O presente trabalho teve como objetivo desenvolver e validar os métodos de eletroforese capilar (CE) e cromatografia líquida de alta eficiência (HPLC) para determinar a eficiência de encapsulação do fármaco imatinibe em nanopartículaspreviamente elaboradas e caracterizadas, assim como estudar sua liberação in vitro por CE. As nanopartículas foramdesenvolvidas pelo método de nanoprecipitaçãoe caracterizadas quanto ao tamanho, potencial zeta, morfologia e eficiência de encapsulação. A eletroforese capilar é uma técnica alternativa muito promissora em relação ao HPLC devido ao seu baixo custo, menor tempo de corrida e menos poluente ao meio ambiente. Os métodos de quantificação por CE e HPLCforam desenvolvidose validadossegundo as diretrizes do ICH, Farmacopeia Americana e ANVISA, permitindo desenvolver um estudo de liberação.As nanoesferas desenvolvidas apresentaram diâmetro médio próximo a 150nm, com índice de polidispersão menor que 0,1 e aproximadamente 90% de eficiência de encapsulação. Ambos métodos se mostraram lineares com coeficientes de determinação superiores a 0,99, os métodos se mostraram precisos (%DPR< 2), exatos(101,0±4,2% e 98,0±2,5% para HPLC e CE, respectivamente)e seletivos.O método de CE permitiu desenvolver um método de estudo de liberação independente das membranas de diálise. / In recent years, there has been a growing number of researches involving nanotechnology to obtain controlled release drugs, these systems can: protect the drug against biological and physico-chemical incompatibilities; controlling the bioavailability of the drug. Although with all these advantages there are no in vitro methods really capable of accurately predicting drugs release by such systems, therefore, the development of in vitro release methods to determine the release kinetics of such systems is very important. The objective of the present work was to develop and validate capillary electrophoresis (CE) and HPLC methods to determine the encapsulation efficiency of the imatinib drug in previously elaborated and characterized nanoparticles, as well as to study its release in vitro by CE method. The nanoparticles were synthesized using the nanoprecipitation method and characterized by size, zeta potential, morphology and encapsulation efficiency. Capillary electrophoresis is a very promising alternative to HPLC because of its low cost, less runtime and less polluting environment. The CE and HPLC methodswere developed and validated according ICH, American Pharmacopoeia and ANVISA guidelines.Developed nanospheres had an average diameter close to 150nm, with polydispersity index less than 0.1 and approximately 90% encapsulation efficiency. Both methods were linear with determination coefficients higher than 0.99, the methods were precise (%RSD < 2), accurate (101.0±4,2% and 98.0±2,5% for HPLC and CE, respectively) and selective. Capillary electrophoresis method allowed to develop a drug release study independent of dialysis membranes.

Die Organtransplantation stellt ein therapeutisches Verfahren für Patienten mit irreversibel geschädigten Organen dar. Doch weist dieses Behandlungskonzept weiterhin einen wesentlichen Nachteil auf: noch immer wird der langfristige Erfolg der Therapie zu oft durch die so genannte Transplantatabstoßung gefährdet. Hierbei handelt sich um eine vom Organtransplantat ausgelöste Immunantwort, die zu dessen Zerstörung führt. Die derzeit einzige Möglichkeit eine Abstoßung zu verhindern, ist die Unterdrückung des Immunsystems mit so genannten Immunsuppressiva. Auch wenn diese erstmals in den 60er Jahren des 20. Jahrhunderts erfolgreich eingesetzten Medikamente ständig verbessert werden, bleiben die von ihnen ausgelösten Nebenwirkungen weiterhin ein ernstzunehmendes Problem. Sie unterdrücken die gesamte körpereigene Abwehr, was zum Schutz der Organtransplantate vor Abstoßung gewünscht ist, doch fördern sie hierdurch die Entstehung von Tumoren und Infektionen. Bei der Transplantatabstoßung handelt es sich um eine von CD4+ T-Lymphozyten ausgelöste Immunantwort. Diese Lymphozyten werden von allogenen Peptiden, die von Spender-MHC-Molekülen stammen, über den indirekten Weg der Alloantigenerkennung aktiviert. An der Transplantatabstoßung ist zwar eine Vielzahl von Alloantigenen beteiligt, doch ist es möglich, Peptidantigene zu identifizieren, die einen nachweisbaren Effekt auf die Transplantatabstoßung ausüben. So wurde in der eigenen Arbeitsgruppe die für die Abstoßung allogener Organtransplantate beteiligten MHC (RT1u)-Peptidantigene charakterisiert. Insbesondere die Bedeutung des aus 19 Aminosäuren bestehenden allogenen Peptids P1 für die Alloimmunantwort wurde intensiv untersucht. So weisen P1-spezifische T-Lymphozyten ein ausgeprägtes Th1-Cytokin-Muster auf und beschleunigen die Abstoßung von Wistar-Furth-Organtransplantaten in Lewis-Ratten. Das Ziel dieser Arbeit war die Charakterisierung des T-Zellrezeptor Vb-Repertoires P1-spezifischer T-Lymphozyten mit der Methode des PCR-ELISA. In einem ersten Schritt wurden Thymozyten und T-Lymphozyten unterschiedlicher Lymphknotenstationen untersucht. Thymozyten exprimierten alle 22 TCR Vb-Elemente und einzig TCR Vb14 war überrepräsentiert. Die T-Lymphozyten der cervikalen, mesenterialen, iliakalen und poplitealen Lymphknoten zeigten ebenfalls eine charakteristische Überexpression bestimmter TCR Vb-Elemente. So exprimierten cervikale T-Lymphozyten bevorzugt die TCR Vb-Elemente 2, 6, 8.3 und 16, mesenteriale T-Lymphozyten die TCR Vb-Elemente 2, 4, und 8.1, illiakale T-Lymphozyten die TCR Vb-Elemente 2 und 6 und popliteale T-Lymphozyten die TCR Vb-Elemente 2, 4 und 9. Die Immunisierung mit dem nicht-immunogenen Kontrollpeptid (Autoantigen) Ac führte zu einer leichten Veränderung des T-Zellrezeptor-Repertoires, bei der die TCR Vb-Elemente 14 und 16 überexprimiert waren. Das Adjuvant TiterMax beeinflusste kaum das TCR Vb-Repertoire. Die Immunisierung mit dem allogenen Peptid P1 führte zu einer eindeutigen Beeinflussung des T-Zellrezeptor-Repertoires. Popliteale T-Lymphozyten, die 7 Tage nach Immunisierung analysiert wurden, zeigten ein Repertoire, bei dem die TCR Vb-Elemente 15, 16, 17 und 20 überexprimiert waren. Dieses Repertoire war am Tag 3 nach Immunisierung noch nicht so ausgebildet. Wurden die antigenspezifischen T-Lymphozyten nach ihrer Isolierung mit P1 in vitro restimuliert, so waren in diesem T-Zellrezeptor-Repertoire die TCR Vb-Elemente 8.3, 15, 16 und 20 überexprimiert. Zum Vergleich: in naiven T-Lymphozyten waren die Vb-Elemente 2, 4 und 9 überexprimiert. Damit war es zu einer deutlichen Verschiebung im T-Zellrezeptor-Repertoire antigenspezifischer T-Lymphozyten gekommen, die auf das Peptidantigen P1 zurückzuführen ist. Mit der Methode des PCR-ELISA wurde das T-Zellrezeptor-Repertoire antigenspezifischer T-Lymphozyten bestimmt. Hiermit sind wesentliche Voraussetzungen geschaffen worden, um T-Zellklone zu etablieren und ihre Bedeutung für die Transplantatabstoßung genauer zu untersuchen. / Organ transplantation is an important medical therapy for patients with irreversibly damaged organs. However, this therapeutic intervention has a great disadvantage because the long-term success of organ allografts is still too often endangered by the so called allograft rejection, an immune response directed to the allograft and leading to its destruction. The major approach for the prevention and management of allograft rejection is to suppress the immune system with immunosuppressive agents. These agents were introduced into transplantation medicine in the 1960s and since that time they have been continually improved. However, their side effects remain a seriousness problem because the suppression of the immune defence inhibits the allograft rejection on the one hand but causes infections and increases tumour incidence on the other hand. The allograft rejection is mediated by CD4+ T lymphocytes and the responsible antigens recognized by them are allogenic peptides processed from donor MHC molecules. Although a large number of allgenenic peptides are involved in allograft rejection, it is possible to identify certain peptide antigens involved in allograft rejection. In our group allogeneic peptides from MHC class I molecules from Wistar Furth rats were investigated. The significance of the allogeneic peptide P1, consisting of 19 amino acids, in inducing allograft rejection was analysed in detail. P1-specific T lymphocytes demonstrated a Th1-cytokine dominated profile and accelerated the rejection of allografts in Lewis rats donated by Wistar Furth rats. The aim of this study was to characterise the T cell receptor (TCR) Vb repertoire of P1-specific T lymphocytes with the PCR-ELISA technique. First, thymocytes and T lymphocytes from different lymph nodes were analysed. Thymocytes expressed all 22 TCR Vb elements and only TCR Vb14 was overrepresented. The T lymphocytes of cervical, mesenteric, iliacal und popliteal lymph nodes also demonstrated a certain repertoire of overrepresented TCR Vb elements. In cervical T lymphocytes the expression levels of the TCR Vb elements 2, 6, 8.3 and 16 were increased; in mesenteric T lymphocytes the TCR Vb elements 2, 4 and 8.1; in illiacal T lymphocytes the TCR Vb elements 2 and 6; and in popliteal T lymphocytes the TCR Vb elements 2, 4 and 9. The immunisation with the autoantigen Ac led to a small variation of the TCR Vb repertoire and the TCR Vb elements 14 and 16 were overrepresented. The adjuvant TiterMax did not influence the TCR Vb repertoire. In contrast, the immunisation with the allogeneic peptide P1 clearly influenced the T cell receptor repertoire. Popliteal T lymphocytes analysed 7 days after immunisation demonstrated a TCR Vb repertoire where the TCR Vb elements 15, 16, 17 und 20 were overrepresented. On day 3 after immunisation this repertoire was not yet clearly developed. In P1-specific T lymphocytes restimulated in vitro the expression levels of the TCR Vb elements 8.3, 15, 16 and 20 were increased. In comparison, in naïve T lymphocytes the TCR Vb elements 2, 4 and 9 were overrepresented. These results underline that the immunisation with peptide P1 induces a characteristic TCR Vb repertoire. The TCR Vb repertoire of P1-specific T lymphocytes was analysed with the PCR-ELISA technique. The determination of the T cell receptor repertoire is a prerequisite to establish T cell clones and to analyse their involvement in allograft rejection.

Der Einsatz der Vitamin B 1 Vorstufe Benfotiamin hat sich im Tiermodell durch Verhinderung oder gar Aufhebung typischer diabetischer Folgeschäden wie Ne- phropathie, Retinopathie und Neuropathie ausgezeichnet. Diese Wirkung wird unter anderem der Aktivitätssteigerung des Enzyms Transketolase zugeschrie- ben, welches auch bei Dialysepatienten ohne diabetische Grunderkrankung sup- primiert ist. Das Ziel der vorliegenden Arbeit war, die Auswirkungen einer ora- len Benfotiaminsubstitution auf den Stoffwechsel von Langzeithämodialysepati- enten zu untersuchen. Die 15 rekrutierten Patienten mit und ohne Diabetes mel- litus erhielten über einen Zeitraum von 2 Monaten eine Dosis von 300 mg/d Benfotiamin, die in den folgenden 2 Monaten bis maximal 450 mg/d gesteigert wurde. Um einen Eindruck über den Verlauf der Entzündungssituation und des oxidativen Stresses zu gewinnen, wurden im Patientenvollblut AGEs und pro- inflammatorische Zytokine gemessen. Außerdem wurden peripheren Lympho- zyten mit Hilfe des alkaline Comet-Assay und des Mikrokerntestes auf DNA- Schädigungen analysiert. In beiden Patientengruppen lässt die Senkung der Mi- krokernraten den Schluss zu, dass Benfotiamin DNA-Schäden und somit eventu- ell das Krebsrisiko reduziert. Dieses vielversprechende Ergebnis korreliert jedoch nicht mit dem Resultat des Comet-Assay. Da hier der relative DNA-Schaden ten- dentiell ansteigt, sollte es Ziel weiterer Studien sein, diesen Sachverhalt an ei- nem größeren Patientenkollektiv mit Kontrollgruppen zu überprüfen. Eventuell ist letzteres Testsystem wegen seiner hohen Sensitivität in diesem Fall nicht op- timal geeignet. Außerdem sollte gezielt auf die beobachtete schnellere und stär- kere Mikrokernsenkung der diabetischen Patienten eingegangen werden, da die- se in der vorliegenden Studie zahlenmäßig unterrepräsentiert waren. Positiv zu bewerten ist der leichte CRP-Abfall sowie der Anstieg des Gesamtproteins und Albumin im Serum, was auf eine Reduktion der Mikroinflammation und oder eine verbesserte Ernährungssituation hinweist. Andererseits spricht der Anstieg des Neopterin- und Interleukin 6-Spiegels gegen die Veränderung des Inflamma- tionsstatus. Entgegen der Erwartung ließ sich in dieser Studie keine Reduktion der zirkulierenden AGEs und AOPPs im Serum erzielen. Um eine Reduktion des oxidativen Stresses besser beurteilen zu können, sollten in Folgestudien direkte und leicht veränderliche Marker wie der Glutathionspiegel verwendet werden. Zusammenfassend reduzierte Benfotiamin bei Hämodialysepatienten mit und ohne Diabetes mellitus DNA-Schäden in peripheren Lymphozyten bei unver- änderter Inflammationssituation und steigerte die Plasmaproteinkonzentration. Dies wurde eventuell durch Reduktion von oxidativem Stress und oder Beein- flussung seiner Ursachen wie Reduktion von Urämietoxinen erreicht.Weitere kli- nische Studien sind notwendig, um dieses vielversprechende Medikament in der täglichen Praxis einsetzen zu können. Besonders vorteilhaft ist seine gute Verträg- lichkeit auch in hoher Dosierung. Darüber hinaus soll das Präparat auch neuro- patische Schmerzen reduzieren, die sich bei Dialysepatienten häufig manifestie- ren, und wirkt somit multikausal. / It has been shown in animal models, that Benfotiamine, a precursor of the vitamine B1, prevents typical complications of diabets, like nephropathy, retinopathy and neuropathy. This effect is attributed to the increased activity of the enzyme trankelotase. The latter is also suppressed in patients of the hemodialysis program who are not diabetic. The goal of this thesis was to show the effects of an oral administration of benfotiamine on longterm hemodialysis patients. Fifteen patients were treated with 300 mg per day of benfotiamine which was increased in the following two months to 450 mg per day. The patient group consisted of a sub-group of diabetic and non-diabetic individuals. Advanced glycation endproducts (AGEs) and proinflammatory cytocines were measured in patients full-blood to show the impact on the inflammation and the oxidative stress situation. The DNA-damage in peripheral lymphocytes was determined using the alkaline comet-assay and the micronucleus-assay. The rate of micronuclei was diminished in both patient groups which could be attributed to the reduction of DNA-damage by benfotiamine and so eventually to a reduced risk of cancer. However, this result does not agree with the comet-assay experiments. The relative DNA-damage increased in the course of the study and so seems to be unaffected by the benfotiamine therapy. This may be attributed to the high sensitivity of the comet-assay technique. Therefore, further investigations with a bigger patient group in a double-blind study are necessary. Additionally, there should be a greater focus on diabetic patients that showed a faster and increased reduction of micronuclei which were underrepresentated in this study. The slight reduction of CRP and the increased protein and serum-albumine concentration correlates to a better nutritional status. On the other hand, the increasing neopterine and interleukine 6 level do not agree to the changes in the inflammatory situation. Against all expectations there was no reduction of AGEs and AOPPs in patients serum. Following studies should focus on rapidly changing direct markers like the glutathione level. In summary, benfotiamine reduces DNA-damage in peripheral lymphocytes in hemodialysis patients with or without diabetes. The plasma protein concentration was increased but unexpectedly the inflammatory situation was stable. These effects may be due to a reduction of oxidative stress or its causes like diminished ureamic toxines. One of Benfotiamines advantages is its good tolerance, even in increased dosages. Furthermore it seems to diminish neuropathic pain which is frequent in hemodialysis patients. However, more clinical studies are neccessary for a use in daily practice.